TW199896B - - Google Patents

Download PDF

Info

Publication number
TW199896B
TW199896B TW080105043A TW80105043A TW199896B TW 199896 B TW199896 B TW 199896B TW 080105043 A TW080105043 A TW 080105043A TW 80105043 A TW80105043 A TW 80105043A TW 199896 B TW199896 B TW 199896B
Authority
TW
Taiwan
Prior art keywords
group
compound
formula
shows
ministry
Prior art date
Application number
TW080105043A
Other languages
English (en)
Chinese (zh)
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Application granted granted Critical
Publication of TW199896B publication Critical patent/TW199896B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW080105043A 1990-07-04 1991-06-28 TW199896B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90401940 1990-07-04

Publications (1)

Publication Number Publication Date
TW199896B true TW199896B (enExample) 1993-02-11

Family

ID=8205733

Family Applications (1)

Application Number Title Priority Date Filing Date
TW080105043A TW199896B (enExample) 1990-07-04 1991-06-28

Country Status (22)

Country Link
US (2) US5538978A (enExample)
EP (1) EP0465297B1 (enExample)
JP (1) JP3006919B2 (enExample)
KR (1) KR100217807B1 (enExample)
CN (1) CN1031713C (enExample)
AT (1) ATE133678T1 (enExample)
AU (1) AU643533B2 (enExample)
CA (1) CA2045783C (enExample)
DE (1) DE69116750T2 (enExample)
DK (1) DK0465297T3 (enExample)
ES (1) ES2085446T3 (enExample)
FI (1) FI101793B (enExample)
GR (1) GR3019793T3 (enExample)
HU (1) HU208832B (enExample)
IE (1) IE72096B1 (enExample)
IL (1) IL98702A (enExample)
MX (1) MX9203682A (enExample)
NO (1) NO180541C (enExample)
NZ (1) NZ238774A (enExample)
PT (1) PT98198B (enExample)
TW (1) TW199896B (enExample)
ZA (1) ZA914978B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69116750T2 (de) * 1990-07-04 1996-11-14 Merrell Dow Pharma 9-Purinyl-Phosphonsäurederivate
EP0531597A1 (en) * 1991-09-12 1993-03-17 Merrell Dow Pharmaceuticals Inc. Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine
US5817661A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5723466A (en) * 1991-12-06 1998-03-03 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5817672A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5817660A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
CA2084222C (en) * 1991-12-06 2004-04-06 David R. Borcherding Novel trans cyclopentanyl purine analogs useful as immunosuppressants
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
CA2171868A1 (en) * 1993-09-17 1995-03-23 Petr Alexander Method for dosing therapeutic compounds
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
MY141789A (en) * 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
EP1509537B9 (en) 2002-04-26 2007-11-14 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
KR20060022647A (ko) 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
JP5069463B2 (ja) 2003-04-25 2012-11-07 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス性ホスホネート類似物
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
EP2145888A1 (en) 2003-09-18 2010-01-20 Conforma Therapeutics Corporation Deazapurine derivatives as HSP90-Inhibitors
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
EP1678322A2 (en) 2003-10-24 2006-07-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2005044279A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
EP1706405B1 (en) 2003-12-22 2009-03-04 Gilead Sciences, Inc. 4'-substituted carbovir- and abacavir-derivatives as well as related compounds with hiv and hcv antiviral activity
ES2720618T3 (es) 2004-07-27 2019-07-23 Gilead Sciences Inc Análogos de fosfonato de compuestos de inhibidores de VIH
BRPI0609509A2 (pt) 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável
US8158108B2 (en) * 2006-06-28 2012-04-17 S.C. Johnson & Son, Inc. VOC-free compressed gas aerosol compositions
US8178078B2 (en) 2008-06-13 2012-05-15 S.C. Johnson & Son, Inc. Compositions containing a solvated active agent suitable for dispensing as a compressed gas aerosol
NZ590075A (en) 2008-07-08 2012-12-21 Gilead Sciences Inc citrate, malonate and succinate salts of the HIV inhibitor ethyl N-[(S)({ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy} methyl)phenoxyphosphinoyl]-L-alaninate
KR101692133B1 (ko) 2015-01-13 2017-01-02 연세대학교 원주산학협력단 폴리이미드 수용액을 이용한 폴리이미드 성형방법
CN105061504A (zh) * 2015-09-16 2015-11-18 湖南大学 P-炔基磷酸酯类化合物的制备方法
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984004748A1 (en) * 1983-05-24 1984-12-06 Stanford Res Inst Int Novel antiviral agents
CA1288098C (en) * 1984-08-24 1991-08-27 Richard L. Tolman 4-(guanin-9-yl)butanals and their 3-oxa, 3-thia and 2-ene derivatives having antiviral and antitumor activity
US4988702A (en) * 1986-08-26 1991-01-29 Warner-Lambert Company Novel 9-deazaguanines
EP0328834A1 (en) * 1988-02-16 1989-08-23 Merrell Dow Pharmaceuticals Inc. Novel aspartate transcarbamylase inhibitors
EP0335770B1 (en) * 1988-04-01 1997-01-15 Merrell Pharmaceuticals Inc. Novel fluorophosphonate nucleotide derivatives
US4927830A (en) * 1988-04-08 1990-05-22 The Regents Of The University Of Michigan Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents
EP0338168A1 (en) * 1988-04-19 1989-10-25 Merrell Dow Pharmaceuticals Inc. Phosphonoalkylpurine derivatives
ATE98249T1 (de) * 1988-04-19 1993-12-15 Merrell Dow Pharma Phosphonoalkylpurin-derivate.
JPH02124898A (ja) * 1988-04-28 1990-05-14 Nippon Kayaku Co Ltd プリン塩基を有する新規化合物、その用途及び中間体
JPH02124897A (ja) * 1988-07-28 1990-05-14 Nippon Kayaku Co Ltd エリスロフラノシルヌクレオシド誘導体の製造法及び新規誘導体
GB8827339D0 (en) * 1988-11-23 1988-12-29 Wellcome Found Antiviral compounds
EP0374096B1 (de) * 1988-12-14 1992-12-02 Ciba-Geigy Ag 2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür
DE69116750T2 (de) * 1990-07-04 1996-11-14 Merrell Dow Pharma 9-Purinyl-Phosphonsäurederivate
EP0468119A1 (en) * 1990-07-24 1992-01-29 Merrell Dow Pharmaceuticals Inc. Novel carbocyclic analogs of certain nucleosides
EP0477454A1 (en) * 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides

Also Published As

Publication number Publication date
KR920002622A (ko) 1992-02-28
PT98198B (pt) 1998-12-31
HUT59151A (en) 1992-04-28
DE69116750D1 (de) 1996-03-14
NO180541B (no) 1997-01-27
NO912606L (no) 1992-01-06
HU912253D0 (en) 1991-12-30
GR3019793T3 (en) 1996-07-31
KR100217807B1 (ko) 1999-10-01
US5527803A (en) 1996-06-18
CN1031713C (zh) 1996-05-01
FI101793B1 (fi) 1998-08-31
ES2085446T3 (es) 1996-06-01
EP0465297B1 (en) 1996-01-31
IL98702A (en) 1997-02-18
AU643533B2 (en) 1993-11-18
FI913236A0 (fi) 1991-07-03
NO912606D0 (no) 1991-07-03
ATE133678T1 (de) 1996-02-15
NO180541C (no) 1997-05-07
FI101793B (fi) 1998-08-31
DE69116750T2 (de) 1996-11-14
CA2045783A1 (en) 1992-01-05
EP0465297A1 (en) 1992-01-08
FI913236L (fi) 1992-01-05
NZ238774A (en) 1993-08-26
IL98702A0 (en) 1992-07-15
ZA914978B (en) 1992-04-29
HU208832B (en) 1994-01-28
JP3006919B2 (ja) 2000-02-07
DK0465297T3 (da) 1996-02-19
MX9203682A (es) 1992-08-01
CN1058021A (zh) 1992-01-22
IE72096B1 (en) 1997-03-12
IE912329A1 (en) 1992-01-15
PT98198A (pt) 1992-04-30
AU7941491A (en) 1992-01-09
CA2045783C (en) 2001-09-18
US5538978A (en) 1996-07-23
JPH04253989A (ja) 1992-09-09

Similar Documents

Publication Publication Date Title
TW199896B (enExample)
TW420612B (en) Pharmaceutical composition for the treatment of HBV infection in a human or other host animal
TW199861B (enExample)
US7495006B2 (en) 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation
JPH10508288A (ja) 置換された０▲上６▼−ベンジルグアニンおよび６（４）−ベンジルオキシピリミジン
CN102272134A (zh) Toll样受体调节剂
JPS61171481A (ja) 新規なプリン誘導体
CA2468071A1 (fr) Derives de triazolo[4,3-a]pyrido[2,3-d]pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
JP2001508469A (ja) ピリミジノン化合物、これを含有する医薬組成物およびその製造方法
JPH0245423A (ja) 抗ウイルス性組合わせ剤
JPH07505380A (ja) ガン治療に使用するためのメラミン誘導体
JPS6345279A (ja) 新規ピリド〔２，３−ｄ〕ピリミジン誘導体、その製造方法並びに該化合物を含有する医薬組成物
JPH013197A (ja) 抗ウイルス化合物およびそれを含有する抗ウイルス剤
JPS6013767A (ja) ピリミジン誘導体
BE882315A (fr) Composes de 6-aryl pyrimidine, leur preparation et leur utilisation
HU204280B (en) Process for producing phosphono-alkyl-purine derivatives and pharmaceutical compositions containing them as active components
JPH04253914A (ja) 抗ｈｂｖピリミジンヌクレオシド
JPS62267230A (ja) 抗ウイルス剤
JPH01319487A (ja) イミダゾ［２，１−ｂ］ベンゾチアゾール誘導体及び該化合物を有効成分とする抗潰瘍剤
JPH03503050A (ja) 抗レトロウイルス剤としてのピリミジンおよびプリン１，２‐ブタジエン‐４‐オール
JPH0660131B2 (ja) ｇｅｍ−ジハロ及びテトラハロ−１，１２−ジアミノ−４，９−ジアザドデカン類
JPS59176299A (ja) 脈管形成因子阻害剤
JP2003252875A (ja) 新規プリン誘導体
Moustafa et al. Synthesis of certain uracil-6-yl or tetrazol-5-ylpyrazolin-5-one and pyrazole derivatives as potential anti-inflammatory agents
TWI357330B (en) Mixture of crystalline forms of triazolo (4,5-d) p